In contrast, pateclizumab, a specific blocker of LTA, showed much-reduced efficacy compared to the TNF blocker adalimumab in a clinical trial for rheumatoid arthritis, which may call into question the risky role of LTA in bone [39]. Here, TNF is linked to rheumatoid arthritis.